Minor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies.
Isabell M Meier, Martin Trøstheim, Eira N Jensen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined whether blocking opioid receptors increases pain in healthy volunteers undergoing peripheral pain testing. It included 67 double-blind, randomised, placebo-controlled studies (N = 2706) of centrally active opioid antagonists. Across pain outcomes, mu-opioid blockade was associated with slightly higher pain than placebo (Hedges' g [95% CI] = 0.18 [0.11, 0.25]), equivalent to an increase of 2.8 points on a 0 to 100 pain intensity scale. The authors concluded that endogenous opioids have a minor role in human pain regulation, while noting evidence that the pooled effect may be overestimated.
Key findings
- Mu-opioid blockade was associated with higher pain than placebo: Hedges' g [95% CI] = 0.18 [0.11, 0.25].
- The pooled difference corresponded to an increase of 2.8 points on a 0 to 100 pain intensity scale.
- Residual heterogeneity was substantial (I 2 = 66%), and study characteristics explained little or none of it.
- The most credible evidence of endogenous opioid pain regulation was found for placebo hypoalgesia.
Why it matters
The findings qualify the common view of endogenous opioids as major regulators of acute pain: receptor blockade produced only a small average increase in pain in healthy volunteers. This helps contextualise the biological rationale for opioid analgesia, while the heterogeneity and possible reporting bias caution against treating the pooled estimate as a uniform effect across pain settings.
What to keep in mind
The evidence was heterogeneous (I 2 = 66%), study characteristics explained little or none of this variance, and reporting-bias analyses suggested the effect was slightly overestimated. The studies involved healthy volunteers and peripheral pain testing.